Table 1.
Patient Characteristics for all patients. Data are represented as median (interquartile range) or frequency (percentage).
| PSA < 2.5ng/ml | PSA ≥ 2.5ng/ml | |
|---|---|---|
| N=399 | N=5731 | |
| Age at surgery (years) | 58 (53, 63) | 60 (55, 65) |
| Preoperative PSA (ng/ml) | 1.65 (1.07, 2.18) | 5.90 (4.55, 8.20) |
| Preoperative 5-year recurrence-free probability (%) | 97 (96, 98) | 94 (88, 96) |
| Clinical stage ≥ T2 | 228 (57%) | 1820 (32%) |
| Biopsy Gleason grade | ||
| ≤ 6 | 311 (78%) | 3602 (63%) |
| 7 | 72 (18%) | 1765 (31%) |
| ≥ 8 | 16 (4%) | 364 (6%) |
| Pathology Gleason grade (n=6062) | ||
| ≤ 6 | 213 (53%) | 1985 (35%) |
| 7 | 160 (40%) | 3266 (57%) |
| ≥ 8 | 17 (4%) | 421 (7%) |
| Extracapsular extension (n=6070) | 59 (15%) | 1629 (29%) |
| Seminal vesicle invasion (n=6093) | 10 (3%) | 382 (7%) |
| Positive surgical margins (n=6095) | 43 (11%) | 1339 (23%) |
| Lymph node involvement* | 8 (2%) | 192 (3%) |
| Non-organ confined** (n=6056) | 62 (16%) | 1711 (30%) |
*
Patients without a lymph node dissection (n=1797) were considered as having negative lymph nodes.
**
Presence of extracapsular extension, seminal vesicle invasion, or lymph node involvement